GEP-NETs, gastroenteropancreatic neuroendocrine tumors.
References: 1. Lutathera. Prescribing information. Novartis Pharmaceuticals Corp. 2. Strosberg J, El-Haddad G, Wolin E, et al; for the NETTER-1 trial investigators. Phase 3 trial of 177Lu-dotatate for midgut neuroendocrine tumors. N Engl J Med. 2017;376(2):125-135.
References: 1. Lutathera. Prescribing information. Novartis Pharmaceuticals Corp. 2. Strosberg J, El-Haddad G, Wolin E, et al; for the NETTER-1 trial investigators. Phase 3 trial of 177Lu-dotatate for midgut neuroendocrine tumors. N Engl J Med. 2017;376(2):125-135.